Postdental procedure bacteremia is common and troublesome. The comparative efficacy of multiple prophylactic interventions is unclear. We compared the efficacy of interventions for the prevention of postdental procedure bacteremia. We conducted a review of ClinicalKey, Cochrane CENTRAL, Embase, ProQuest, PubMed, ScienceDirect, Web of Science, and ClinicalTrials.gov from inception to December 4, 2018. Randomized controlled trials that evaluated prophylactic interventions for the prevention of postdental procedure bacteremia were eligible. The primary outcome was the incidence of postdental procedure bacteremia. A total of 24 trials were included with 2,147 participants. Our network meta-analysis demonstrated that intravenous administration of 1,000/200 mg of amoxicillin/ clavulanate provided the least incidence of postdental procedure bacteremia among all the prophylactic interventions (odds ratio = 0.03, 95% CI = 0.00 to 0.63) as compared with the placebo/controls. Oral 3 g of amoxicillin had the least incidence of postdental procedure bacteremia among all oral or topical forms of prophylactic interventions (odds ratio = 0.10, 95% CI = 0.02 to 0.44) as compared with the placebo/controls. No serious adverse events, such as anaphylactic shock, mortality, and the development of antibiotic-resistant bacteria, were reported. None of the included subjects were of high risk of infectious endocarditis. Our network meta-analysis demonstrates that intravenous amoxicillin/clavulanate and oral amoxicillin might be the best prophylactic interventions in preventing postdental procedure bacteremia among all the oral/topical forms of interventions for the overall populations.
Introduction
Postdental procedure bacteremia is a highly prevalent condition, ranging from 58% to 100% in adults and 30% to 76% in children (Tomas and Alvarez 2012) . Several frequent sources of bacteremia, such as viridans streptococci and Streptococcus spp., have been detected in the bloodstream after the dental procedure in nearly half of the patients (Horliana et al. 2014; Mang-de la Rosa et al. 2014) . The presence of odontogenic bacteremia has been associated with the risk of infectious endocarditis (IE) in high-risk patients, as in patients with prosthetic heart valves (Tubiana et al. 2017) , and odontogenic bacteremia accounts for 10% to 15% of episodes of IE's pathogenesis (Barbosa et al. 2015) . As a consequence of IE, the in-hospital mortality rate of IE was as high as nearly 20% (Slipczuk et al. 2013) .
Despite the potential link between the odontogenic bacteremia and IE, the role of prophylaxis in patients receiving dental procedure has received much debate. Some guidelines have recommended prophylaxis, especially antibiotics, citing the high risk of mortality and complication of IE related to odontogenic bacteremia (Gould et al. 2006; Wilson et al. 2007; Habib et al. 2015; Nishimura et al. 2017 ). However, other guidelines oppose antibiotic prophylaxis, citing the increased risk of anaphylactic shock related to antibiotics or the development of antibiotic-resistant bacteria after wide and long-term use of prophylactic antibiotics (Gould et al. 2006; Wilson et al. 2007 ; National Institute for Health and Clinical Excellence 2008; Nishimura et al. 2017 ). However, the cessation of prophylactic antibiotics in line with the aforementioned guidelines has caused concerns about the potential risks in the dramatic increase in IE incidence. A recent report in England found that following the dropping-down prescription rate of prophylactic antibiotics, the incidence of IE had increased to 35 more cases per month in March 2013, above the projected historical trend (Dayer et al. 2015) . However, although the prophylactic antibiotics in patients with a high risk of IE had been admitted to be important by some guidelines (Gould et al. 2006; Wilson et al. 2007; Habib et al. 2015; Nishimura et al. 2017) , it is difficult to conduct well-designed randomized controlled trials (RCTs) directly investigating the benefit and preventive effect of the prophylactic antibiotics to the postdental procedure IE due to its low incidence. Therefore, the investigation of the benefit and preventive effect of bacteremia by individual prophylactic interventions in the general population is of high relevance for clinicians.
There has also been inconsistent results from systematic reviews and traditional pairwise meta-analyses; hence, there is a lack of clarity to informed clinical care and data. For instance, a recent review article indicated that antimicrobial prophylaxis before an invasive dental procedure does not prevent bacteremia (González Navarro et al. 2017 ). Furthermore, although traditional meta-analyses have demonstrated an association of decreased bacteremia with prophylactic chlorhexidine (Arteagoitia et al. 2018) or overall prophylactic antibiotics (Moreno-Drada and Garcia-Perdomo 2016; Cahill et al. 2017) , these metaanalyses could not provide further information about the superiority of individual prophylactic antibiotics. Nevertheless, other review articles provided inconclusive findings. A network meta-analysis (NMA) is a method that enables indirect comparisons of efficacy among different prophylactic agents and can assess and evaluate the comparative efficacies of the different agents.
Given the aforementioned rationale, we conducted an NMA of RCTs that investigated various antimicrobial prophylactic agents used to prevent postdental procedure bacteremia in the participants receiving dental procedure.
Methods

Search Strategy and Selection Criteria
We conducted a systematic review of ClinicalKey, Cochrane CENTRAL, Embase, ProQuest, PubMed, ScienceDirect, Web of Science, and ClinicalTrials.gov from inception to December 4, 2018. We applied the keywords "prevention," "bacteremia," and "dental procedure." No language restriction was put in place. We also conducted manual searches for those potentially eligible articles from the reference lists.
We included published RCTs that were of placebo-or active-controlled design and that included adult or pediatric participants. The active controls included different prophylactic interventions. For topical antiseptics, we followed the rationale of a previous meta-analysis (Arteagoitia et al. 2018) , which analyzed the efficacy of topical antiseptics at any dosage or duration of rinsing as 1 overall group. The exclusion criteria included the following: 1) lack of an adequate control group, 2) no related dental procedures, and 3) no defined bacteremia according to the blood culture result. In case of duplicated usage of data, we included the report with the most informative and largest sample sizes.
Outcome Measures
The primary outcome was the incidence of postdental procedure bacteremia, which was determined by the positive blood culture from the recruited participants after a dental procedure. If one study provided several data of incidence rate of bacteremia in different periods, we chose the one most near the dental procedure. The secondary outcome was the incidence of minor or serious adverse events, such as anaphylactic shock, mortality, and development of antibiotic-resistant bacteria. Two authors independently screened the studies, extracted the relevant data from the manuscripts, and completed an assessment of the risk of bias among the included studies. In cases of a discrepancy, the corresponding author was involved. If there was a lack of eligible data from the manuscripts, we contacted the corresponding authors or coauthors to obtain the original data.
Two independent authors evaluated the risk of bias for each domain described in the Cochrane risk of bias tool (Higgins and Green 2009 ).
Data Synthesis and Analysis
Given the assumption of consistency and transitivity (Tonin et al. 2017) , we performed the NMA with Stata 14.0 with the network package (StataCorp). For categorical data, we estimated the summary of odds ratios with 95% CIs. We used random effect models in our pairwise meta-analysis and frequentist models in our NMA to compare the effect sizes among studies with the same interventions. The heterogeneity among the included studies was evaluated with the tau value, which is the estimated standard deviation of the treatment effect across the included studies. A mixed treatment comparison with generalized linear mixed models was used to analyze the direct and indirect comparisons among the NMAs. We calculated the relative ranking probabilities among the treatment effects of all interventions for the target outcomes. In brief, the surface under the cumulative ranking curve (SUCRA) reflected the percentage of effectiveness that each intervention can achieve relative to an imaginary intervention that was the best without uncertainty. We also evaluated 1) the potential local inconsistency by using the loop-specific approach and the side-splitting method and 2) the global inconsistency by using the design-bytreatment interaction model.
Finally, we evaluated the quality of evidence according to the Cochrane handbook for Grading of Recommendations, Assessment, Development and Evaluations (GRADE) ratings (Schunemann et al. 2013 ) for quality assessment.
Results
A total of 101 articles were considered for full text review (Fig.  1) , and 77 articles were excluded for various reasons (Appendix Table 1 ). In brief, 24 articles with 2,147 participants (mean age = 32.4 y, mean female proportion = 48.9%) were included in the current study (to see detailed characteristics of the included studies, adverse events reported in each study, and information of the dental procedure applied in each study, see Appendix Tables 2-4, respectively). The whole geometric distribution of the treatment arms is provided in Appendix Figure 1A . The time of blood drawn for blood culture after a dental procedure ranged from 2 min to 7 d (median = 15 min, 25% to 75% quantile = 9 to 60 min). The overall incidence rate of bacteremia was 30.8% (24.8% in the active intervention groups and 41.2% in the placebo/control groups). None of the participants finally developed IE among all the included RCTs. Although we did not set any limitations on the participants' characteristics during our literature selection stagesuch that we could include both participants with a high risk of IE and those without definite risk factors-none of the included studies recruited participants with a high risk of IE (i.e., prosthetic cardiac valves, pregnancy, immunodeficiency, history of IE, rheumatic heart disease, congenital heart disease). Therefore, we could not perform further subgroup analysis of participants with a high risk of IE.
Primary Outcome: Incidence of Postdental Procedure Bacteremia
In our NMA, the incidence of postdental procedure bacteremia by preventive administration of oral 3 g of amoxicillin (o3Amox), oral 2 g of amoxicillin (o2Amox), intravenous (IV) 50 mg/kg of amoxicillin in children, IV 400 mg of teicoplanin, IV 1,000/200 mg of amoxicillin/clavulanate (IVAmox/Clav), and IV 1.5 g of cefuroxime was significantly less than that of the placebo/control groups (Appendix Table 5A ; Fig. 2 ). According to the SUCRA, IVAmox/Clav provided the least incidence of postdental procedure bacteremia. Among the oral/ topical forms of preventive administration, o3Amox provided the least incidence of postdental procedure bacteremia.
Subgroup Analysis
In the subgroup analysis of the incidence of postdental extraction bacteremia and postdental procedure bacteremia in adult participants, the main findings of our NMA revealed similar findings with those observed in overall dental procedures (for the whole result of subgroup analysis, see Appendix Table 5B -E and Appendix Figs. 1B-E and 2; Figs. 3-5). However, the subgroup analysis of the incidence of postdental procedure bacteremia in local/general anesthesia had different findings from the overall dental procedures. In local anesthesia, the incidence of postdental procedure bacteremia by preventive oral 500 mg of azithromycin (o500Azith) and rinsed povidoneiodine solution was also significantly less than that of the placebo/control groups. The SUCRA revealed that o500Azith and o3Amox both provided the least incidence of postdental procedure bacteremia. In general anesthesia, the incidence of postdental procedure bacteremia by the preventive administration of rinsed chlorhexidine and oral 400 mg of moxifloxacin (o400Moxif) was also significantly less than that of the placebo/control groups. The SUCRA revealed that IVAmox/ Clav provided the least incidence of postdental procedure bacteremia.
Records identified (n=217)
Duplicated records excluded (n=57) Records after duplicates removed (n=160) Excluded by title and abstract (n=59) Full-text articles assessed for eligibility (n=101) Articles (n=77) Figure 1 . Flowchart of the current network meta-analysis.
Adverse Events: Minor or Serious
Only 3 studies reported data considering minor adverse events, including the bitter taste of povidone-iodine solution, gastrointestinal discomfort, mild diarrhea, skin rash, nausea, and pain in the injection site. None of the studies addressed the following serious adverse events: anaphylactic shock, mortality, and development of antibiotic-resistant bacteria.
Risk of Bias and Publication Bias
We found that 44.8%, 44.2%, and 11.0% of our studies had an overall low, unclear, and high risk of bias, respectively. Funnel plots and the Egger's test revealed no significant publication bias among the articles included in our NMA. In general, NMAs did not demonstrate inconsistency. The results of GRADE evaluation is listed in the Appendix.
Discussion
To the best of our knowledge, this is the first NMA addressing the preventive effect of individual prophylactic interventions to the prevention of postdental procedure bacteremia. Among all the prophylactic interventions, IVAmox/Clav provided the least incidence of bacteremia. Among the oral/topical forms of preventive administration, o3Amox provided the least incidence of bacteremia. None of the topical antiseptic management was superior to the placebo/controls in our NMA. The main results would not change in the subgroups of dental extraction and adult-only trials. In case of general anesthesia, IVAmox/Clav provided the least incidence of postdental procedure bacteremia; similarly, in case of local anesthesia, o500Azith and o3Amox both provided the least incidence of postdental procedure bacteremia. Finally, only 3 studies addressed minor adverse events, and none of the included studies reported serious adverse events, such as anaphylactic shock, mortality, and development of antibiotic-resistant bacteria.
The main finding of our current NMA was that IVAmox/ Clav (IV infusion after anesthetic induction) provided the least incidence of postdental procedure bacteremia among all the investigated interventions. Evidence had suggested that the antimicrobial activity of penicillin against certain odontogenic bacteria would decrease due to the presence of resistant bacteria, such as viridans streptococci or some other Gram-negative anaerobic bacteria (Kuriyama et al. 2007; Limeres Posse et al. 2016 ). Furthermore, a previous report based on bacterial culture from skin scrapings and saliva samples found that Staphylococcus aureus and viridans streptococci were highly resistant to amoxicillin (53% and 17%, respectively) but were sensitive to amoxicillin and clavulanate (only 13% and 7% Figure 2 . Forest plot of network meta-analysis of incidence of bacteremia after overall dental procedure. Figure 2 indicates that, when the effect size is <1, it means less incidence of bacteremia by preventive management as compared with the placebo/control groups. chlorhexidine: rinse chlorhexidine; control, control/placebo; essentialoil, rinse essential oil-containing antiseptic; i15cefuroxime, IV 1.5 g of cefuroxime; i1amoxycillin, IM 1 g of amoxicillin; i4teicoplanin, IV 400 mg of teicoplanin; i5amoxicillin, IV 50 mg/kg of amoxicillin in children; iamclavulanate, IV 1000/200 mg of amoxicillin/clavulanate; IM, intramuscular; IV, intravenous; o15erythromycin, oral 1.5 g of erythromycin; o1cefaclor, oral 1 g of cefaclor; o1erythromycin, oral 1 g of erythromycin; o2amoxicillin, oral 2 g of amoxicillin; o2penicillin, oral 2 g of penicillin; o3amoxicillin, oral 3 g of amoxicillin; o4moxifloxacin, oral 400 mg of moxifloxacin; o5azithromycin, oral 500 mg of azithromycin; o6clindamycin, oral 600 mg of clindamycin; ojosamycin, oral 1.5 g of josamycin; povidone, rinse povidone-iodine solution; topamoxicillin, rinse amoxicillin suspension.
Figure 3.
Forest plot of network meta-analysis of incidence of bacteremia after dental extraction. Figure 3 indicates that, when the effect size was <1, it means less incidence of bacteremia by preventive management as compared with the placebo/control groups. chlorhexidine, rinse chlorhexidine; control, control/placebo; essentialoil, rinse essential oil-containing antiseptic; i15cefuroxime, IV 1.5 g of cefuroxime; i1amoxycillin, IM 1 g of amoxicillin; i4teicoplanin, IV 400 mg of teicoplanin; i5amoxicillin, IV 50 mg/kg of amoxicillin in children; iamclavulanate, IV 1000/200 mg of amoxicillin/clavulanate; IM, intramuscular; IV, intravenous; o15erythromycin, oral 1.5 g of erythromycin; o1cefaclor, oral 1 g of cefaclor; o1erythromycin, oral 1 g of erythromycin; o2amoxicillin, oral 2 g of amoxicillin; o2penicillin, oral 2 g of penicillin; o3amoxicillin, oral 3 g of amoxicillin; o4moxifloxacin, oral 400 mg of moxifloxacin; o5azithromycin, oral 500 mg of azithromycin; o6clindamycin, oral 600 mg of clindamycin; ojosamycin, oral 1.5 g of josamycin; povidone, rinse povidone-iodine solution; topamoxicillin, rinse amoxicillin suspension. resistant, respectively) (Groppo et al. 2005) . Additionally, the amoxicillin/clavulanate combination strategy had 2 advantages-that is, the combination strategy produces not only a synergistic antibacterial effect but also an enhanced effect through immune-mediated mechanisms to deal with these 2 odontogenic species (Finlay et al. 2003; Limeres Posse et al. 2016) . Therefore, based on this rationale and the result of our overall NMA, IVAmox/Clav would be considered one of the effective prophylactic interventions in preventing postdental procedure bacteremia.
Another important finding of our current NMA was that o3Amox and o2Amox (1 dose, 1 to 3 h before the procedure) provided the least incidence of postdental procedure bacteremia among all the oral/topical forms of preventive administration. The prophylactic effect of the o3Amox in our current NMA was consistent with the results of the previous RCTs (Vergis et al. 2001; Maharaj et al. 2012) . Similarly, the British Society for Antimicrobial Chemotherapy guidelines in the prevention of postdental procedure bacteremia/IE recommended o3Amox to be the drug of choice in the adult general population (Gould et al. 2006 ). According to the American Heart Association (AHA) guidelines, o2Amox was also recommended as the drug of choice in the adult general population to prevent postdental procedure bacteremia/IE after a dental procedure (Wilson et al. 2007) . Therefore, o3Amox would be the prophylactic antibiotic of choice to prevent postdental procedure bacteremia among all oral or topical forms of prophylactic interventions.
However, for patients who are allergic to amoxicillin, our NMA revealed that o400Moxif (1 dose, 1 to 2 h before the procedure) provided the least incidence of postdental procedure bacteremia among all the oral/topical forms of preventive management. In the previous 2 guidelines by the British Society for Antimicrobial Chemotherapy and the AHA, clindamycin (Gould et al. 2006 ) and cephalexin/clindamycin/azithromycin (Wilson et al. 2007 ) were recommended to be prescribed in cases of allergy to amoxicillin. Moxifloxacin, in vitro, had been proven to fight odontogenic pathogens (Limeres et al. 2005) and could contribute to a low minimum inhibitory concentration to all the streptococci species from iatrogenic bacteremia of oral origin (Tomas et al. 2004) . Therefore, these evidences would support the rationale of o400Moxif as the prophylactic antibiotic of choice in case of allergy to amoxicillin.
The fourth important finding of our NMA was that o500Azith and o3Amox were both considered the best prophylactic interventions in case of local anesthesia. In clinical practice, most patients who need a dental procedure are not required to receive general anesthesia; therefore, setting up an IV line for prophylactic antibiotics is unnecessary. The AHA guidelines also suggested that prophylactic antibiotics should initially be . Forest plot of network meta-analysis of incidence of bacteremia after dental procedure in adult participants only. Figure  4 indicates that, when the effect size is <1, it means less incidence of bacteremia by preventive management as compared with the placebo/control groups. chlorhexidine, rinse chlorhexidine; control, control/placebo; essentialoil, rinse essential oil-containing antiseptic; i15cefuroxime, IV 1.5 g of cefuroxime; i1amoxycillin, IM 1 g of amoxicillin; i4teicoplanin, IV 400 mg of teicoplanin; i5amoxicillin, IV 50 mg/kg of amoxicillin in children; iamclavulanate, IV 1000/200 mg of amoxicillin/clavulanate; IM, intramuscular; IV, intravenous; o15erythromycin, oral 1.5 g of erythromycin; o1cefaclor, oral 1 g of cefaclor; o1erythromycin, oral 1 g of erythromycin; o2amoxicillin, oral 2 g of amoxicillin; o2penicillin, oral 2 g of penicillin; o3amoxicillin, oral 3 g of amoxicillin; o4moxifloxacin, oral 400 mg of moxifloxacin; o5azithromycin, oral 500 mg of azithromycin; o6clindamycin, oral 600 mg of clindamycin; ojosamycin, oral 1.5 g of josamycin; povidone, rinse povidone-iodine solution; topamoxicillin, rinse amoxicillin suspension. Figure 5 . Forest plot of network meta-analysis of incidence of bacteremia after dental procedure in the situation of local anesthesia. Figure 5 indicates that, when the effect size is <1, it means less incidence of bacteremia by preventive management as compared with the placebo/control groups. chlorhexidine, rinse chlorhexidine; control, control/placebo; essentialoil, rinse essential oil-containing antiseptic; i15cefuroxime, IV 1.5 g of cefuroxime; i1amoxycillin, IM 1 g of amoxicillin; i4teicoplanin, IV 400 mg of teicoplanin; i5amoxicillin, IV 50 mg/kg amoxicillin in children; iamclavulanate, IV 1000/200 mg of amoxicillin/clavulanate; IM, intramuscular; IV, intravenous; o15erythromycin, oral 1.5 g of erythromycin; o1cefaclor, oral 1 g of cefaclor; o1erythromycin, oral 1 g of erythromycin; o2amoxicillin, oral 2 g of amoxicillin; o2penicillin, oral 2 g of penicillin; o3amoxicillin, oral 3 g of amoxicillin; o4moxifloxacin, oral 400 mg of moxifloxacin; o5azithromycin, oral 500 mg of azithromycin; o6clindamycin, oral 600 mg of clindamycin; ojosamycin, oral 1.5 g of josamycin; povidone, rinse povidone-iodine solution; topamoxicillin, rinse amoxicillin suspension. administered orally and not intravenously and commented that IV antibiotics should be administered only in patients who are unable to tolerate or absorb oral medications (Wilson et al. 2007) . Therefore, the oral form of o500Azith and o3Amox would be a potential choice. However, the evidence of o500Azith was derived from only 1 RCT (Morozumi et al. 2010) , which evaluated the efficacy of o500Azith in subjects with dental scaling. Therefore, the clinician should be careful when applying o500Azith to the other dental procedure.
Finally, our NMA demonstrated that all the topical antiseptic interventions were not superior to that of the placebo/controls in preventing postdental procedure bacteremia in the overall group. These findings were similar to most previous RCTs investigating the preventive effects of topical antiseptic interventions (Vergis et al. 2001; Maharaj et al. 2012 ). These insufficient preventive effects could be due to the poor penetration of these antiseptic medications, such as antimicrobial rinses and irrigations, into the gingival sulcus deeper than 3 mm, where dental bacteria enter into systemic circulation (Lockhart and Schmidtke 1994) . Additionally, the suctioning and irrigation with water during the dental procedure would result in the removal of any retained topical antiseptic agents, thereby diminishing the agents' effect (Vergis et al. 2001) . Therefore, the current evidences could not support the role of topical antiseptic medications in preventing postdental procedure bacteremia.
Several limitations of our current NMA merit further discussion. First, some of the analyses in this study were limited by underpowered statistics, including heterogeneity in the characteristics of the participants (e.g., comorbid diseases, the complexity of the dental health status, age, sex distribution, the environment of blood culture medium used in each trial, and trial duration), the small trial numbers for some treatment arms, and heterogeneity in dental extraction (e.g., single or multiple). Second, although we quantified the individual dosage of oral or IV/intramuscular antibiotics in our NMA, we could not make further quantitative investigation of those topical antiseptic medications, in the aspect of duration or intensity, because of the lack of sufficient data. Third, none of the included studies focused on participants with a high risk of IE, although we tried to include such participants by not setting any limitation on their end during our literature selection stage. In such participants with a high risk of IE, some of them would regularly take prophylactic antibiotics to prevent IE in the long term, which might increase the possibility of developing resistance to antibiotics. Therefore, clinicians should pay special attention when our result is being applied in participants with a high risk of IE because of the high risk of antibiotic resistance. Furthermore, none of the included RCTs reported the development of IE in the recruited participants, indicating that the absolute risk of IE after dental procedures is very small in the general population. Fourth, only 2 trials consisted of "both child and adult" or "child only." Between them, only 1 trial focused on participants <18 y old (Lockhart et al. 2004 ). Therefore, we could not make further analysis focusing on such patients. Fifth, some of the treatment arms (i.e., IVAmox/ Clav and o500Azith) consisted of few RCTs so that the application of the general results to clinical application should be done with care. In addition, because the NMA was a new technique under development, there would be a controversy regarding its application. Sixth, in the current NMA, we followed the rationale to pool the topical antiseptics at any dosage or any rinsing duration into 1 overall group, which might not be able to distinguish the potentially different efficacy of such topical antiseptics (i.e., chlorhexidine) in different dosage or different rinsing duration. Finally, some of the network structures of our current NMA were poorly connected; hence, no sufficient indirect evidences were available to support these findings.
Conclusion and Implication for Research
The main finding of our NMA revealed that IVAmox/Clav provided the least incidence of postdental procedure bacteremia. Regarding the oral/topical forms of preventive administration, o3Amox provided the least incidence of postdental procedure bacteremia. IVAmox/Clav and o500Azith were considered the best prophylactic interventions in the case of general and local anesthesia, respectively. However, because some of the intervention arms were based on few RCTs, the clinical indications should be selected carefully to avoid "one size fits all" treatment to all clinical conditions. The results of the current NMA should not be interpreted as evidence to support prescribing prophylactic agents to prevent IE in the general population receiving dental procedures. Future large-scale RCTs investigating the preventive effect between the prophylactic antibiotics and the incidence of IE related to postdental procedure bacteremia in high-risk patients should be warranted.
